National Administration of Medicines, Food and Medical Technology (ANMAT) The use of daratumumab was permitted For multiple myeloma patients You will not receive a bone marrow transplant. The license is based on Results of the international phase 3 CEPHEUS study Which tested the effectiveness of adding daratumumab to standard chemotherapy. They have been studied More than 700 patients The results showed a very optimistic outlook: In 6 out of 10 patients no myeloma cells are detected With the most sensitive tests, 48.7% achieved heart rate (minimal residual disease) negative, Which means that No new cells are discovered for a year or moreCompared to 26.3% of those who did not use daratumumab.
An additional 19.6% of patients were able to remove traces of myelin using the new drug and increase the time without disease progression.
They discovered that more cooperative mammalian species had significantly fewer cases of cancer
he Multiple myeloma It is a type of cancer that It is found in blood And it originates in Bone marrow plastic cells Which leads to their proliferation uncontrollably and the production of antibodies that lead to adverse results on the immune system because they affect the production of red and white blood cells and platelets, which It can lead to Serious problems such as kidney failure, anemia, bone fractures, And other infections.
In Argentina This announcement gives confidence to multiple myeloma patients because this allows them to take another look at the limited treatments they have received They will be able to access what gives better results, Almost in our country 1,300 cases annually in people between the ages of 50 and 70 years.
Authoritarians don’t like this
The practice of professional and critical journalism is an essential pillar of democracy. This is why it bothers those who believe they are the bearers of the truth.
What is daratumumab?
Daratumumab is a monoclonal antibody directed toward… Attacking a protein found in myeloma cells called CD38, Its mode of action is based on a combination of activation of the immune system and direct cytotoxic effects to destroy multiple myeloma cells.
About The Author
